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Introduction
!
The genus Echinacea (Asteraceae) has beenwidely
used in North America and Europe for the treat-
ment and prevention of upper respiratory tract
infections, such as the common cold and influen-
za [1,2]. Echinacea products were among the
most commonly used dietary supplements for
adults and children according to the NHIS survey
in 2007 [3]. Species of Echinacea, such as E. angus-
tifolia, E. pallida, E. sanguinea, and E. purpurea,
have immune modulatory, antiviral, and antibac-
terial activities [4–6].
Studies with single components and more
complex fractions of Echinacea extracts indicate
that this genus is rich in bioactive chemicals of
which lipophilic alkamides, also known as alkyla-
mides, and ketones, intermediately hydrophilic
phenolic compounds (mainly caffeic-acid deriva-
tives), and polysaccharides are the most recog-
nized for their immunomodulatory properties
[1]. Bauer alkamides 8 [(2E,4E,8Z,10Z)-N-iso-
butyldodeca-2,4,8,10-tetraenamide], 10 [(2E,4E,
8Z)-N-isobutyldodeca-2,4,8-trienamide], and 11
[(2E,4E)-N-isobutyldodeca-2,4-dienamide] at
50 µM and ketone 24 [pentadeca-(8Z,13Z)-diene-
11-yn-2-one] at 5 µM (l" Fig. 1) possess anti-in-
flammatory properties because they significantly
decrease nitric oxide and prostaglandin E (2)
production in lipopolysaccharide-stimulated
RAW264.7 macrophages [7].
Despite many in vitro studies ascribing biological
activities to both the alkamides and ketones,
these activities are possible in vivo only if they
are absorbed. Woelkart et al. [8] found about 5%
of the ingested dose of Bauer alkamide 8 and 1%
of Bauer alkamide 10 in human blood 3 h after
oral administration of a 60% ethanolic extract of
E. angustifolia containing 0.4–2mg of Bauer alka-
mide 8 and 10 (l" Fig. 1). Matthias et al. [9]
showed apparent permeability coefficients (Papp),
ranging from 3 × 10−6 to 3 × 10−4 cm/s for various
alkamides through Caco-2 monolayers, which
were correlated to structural variations in the
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compounds. But few studies have focused on the metabolism of
the alkamides [10], and it is essential to understand alkamide fate
after ingestion because the metabolites may differ in bioactivity
compared with the parent compound [11].
Caco-2 cells are immortalized, human epithelial colorectal ad-
enocarcinoma cells and offer a standard rapid, reliable, and low-
cost model for in vitro prediction of intestinal drug permeability
and absorption [12]. Plant extract matrices may alter absorption
or metabolism and, consequently, the bioavailability of phyto-
chemicals [13], as Ardjomand-Woelkart et al. found that the ab-
solute oral bioavailability of Bauer alkamide 8 with the adminis-
tration of the E. purpurea extract was 1.6-fold higher compared
with the treatment of the pure compound (0.75mg/kg) in rats
[14], thus, matrix effects on the uptake and metabolism of key
components of Echinacea extracts deserve study. Alkamides 8,
10, 11 and ketone 24 were all present in E. pallida and E. sangui-
nea ethanol extracts, but not in E. angustifolia and E.simulata
ethanolic extracts (data not published). Therefore, E. pallida and
E. sanguineawere chosen in this study to investigate the absorp-
tion and metabolism of these compounds.
n-Hexane extracts from the roots of E. pallida, E. angustifolia, and
E. purpurea (30 µg/mL) inhibited multidrug transporter P-glyco-
protein (P‑gp) activity in a human proximal tubular kidney cell
line [15]. P‑gp transporter plays a key role in drug absorption
and distribution because it limits the permeability across the gas-
trointestinal tract [16] by active efflux of potentially toxic sub-
stances back into the intestinal lumen. P‑gp confers resistance to
anticancer chemotherapy through its overexpression in cancer
cells [17]. If Echinacea extracts can block P‑gp, a new paradigm
for circumventing drug resistance might emerge regarding the
uses of these plant materials.
Our hypotheses were that the absorbability of Bauer alkamides
and ketones was dependent on the extract matrix, alkamides
and ketones were glucuronidated, and that ethanolic extracts of
E. pallida and E. sanguinea containing alkamides would inhibit
P‑gp activities in Caco-2 cells. This study was conducted to facili-
tate future studies of the efficacy of these herbs against inflam-
mation and herb-drug interactions.
Materials and Methods
!
Plant extraction
Roots of E. pallida (PI 631293) and E. sanguinea (PI 633672) were
obtained from the USDA‑ARS North Central Regional Plant Intro-
duction Station (NCRPIS), in Ames, Iowa, where they were
cultivated, harvested, dried, and ground (vouchered as original
seed samples, designated as lots PI 631293 97ncao01 SD and PI
633672 97ncao01 SD deposited at the NCRPIS, with images
available at http://www.ars-grin.gov/cgi-bin/npgs/acc/search.pl?
accid=PI+631293 and http://www.ars-grin.gov/cgi-bin/npgs/acc/
search.pl?accid=PI+633672, respectively). Dried Echinacea root
per population (6 g) was extracted with 500mL of 95% ethanol
by Soxhlet percolation for 6 h, filtered, dried by rotary evapora-
tion, and lyophilized. Then the extracts were redissolved in
0.5mL of ethanol (77mg and stored at − 20°C under nitrogen. In-
formation about the specific provenance of both accessions is
available on the Germplasm Resources Information Network da-
tabase at http://www.ars-grin.gov/npgs/acc/acc_queries.html.)
Fig. 1 The chemical structures of Bauer alkamides
8, 10, 11 and ketone 24.
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Bauer alkamide and ketone synthesis
Chemical synthesis of Bauer alkamides and ketones [18] were
conducted according to the procedures described by Wu et al.
[19] and Bae [20]. Alkamide and ketone concentrations were cal-
culated after correcting for percent purity, yielding concentra-
tions equivalent to 100% pure synthetic constituent. Percent pu-
rity before correction, determined by GC‑MS, for Bauer alkamide
8 was 90%, Bauer alkamide 10 was 82%, Bauer alkamide 11 was
92%, and Bauer ketone 24 was 99%. All synthetic Bauer alkamides
and ketones were dissolved in DMSO and stored at − 80°C under
argon gas.
HPLC analysis
HPLC analysis was performed on a Beckman Coulter 126 HPLC,
equipped with a photodiode array detector model 168 and a
model 508 autosampler (Beckman Coulter, Inc.). The mobile
phase was CH3CN/H2O at a flow rate of 1.0mL/min following a
linear gradient of 40–80% CH3CN in H2O over 45min. A re-
versed-phase analytical YMC pack-ODS C18 column (250mm×
4.6mm× 5 µm; Waters Corp.) was used at room temperature.
The detection wavelength was 260 nm and the injection volume
was 100 µL. The limit of detection (LOD), defined as a signal/noise
ratio ≥ 3, was 0.04 µM for Bauer alkamides 8, 10, and 11, and
0.5 µM for Bauer ketone 24.
Transepithelial transfer experiment
Caco-2 cells were obtained from American Type Culture Collec-
tion at passage 18, and all experiments were performed from
passages 30 to 35. The cells were cultured according to Hubatsch
et al. [12]. Cytotoxicity of pure compounds and extracts wasmea-
sured according to Nasser et al. [21]. Pure Bauer alkamides and
ketone 24, at 10–1000 µM, and E. pallida and E. sanguinea ethanol
extracts, at 0.1–50mg/mL, were tested for cytotoxicity. DMSO in
DMEM (Dulbeccoʼs modified Eagleʼs medium, 0.3% v/v; Gibco In-
vitrogen) was used as a control.
After the cells had grown to 90–100% confluency, they were
seeded on collagen-coated polytetrafluroethylene membrane in-
serts (0.45 µm) fitted in bicameral chambers (Transwell-COL,
24mm ID; Corning, Inc.) at 1.2 × 105 cells/cm2. The transepithelial
electrical resistance (TEER) was tested by the Millicell ERS meter
(Fisher Scientific) and only cells with TEER ≥ 250 Ω · cm2 were
used for the permeability study [12]. At 21 days post-seeding,
pure Bauer alkamides and ketone 24, and extracts at noncyto-
toxic concentrations, dissolved in 1.5mL of Hankʼs Buffered Salt
Solution (HBSS, pH 7.4; Gibco Invitrogen), were added to the do-
nor side of the chamber and 1mL of HBSS media was added to
the receiver side. After 15, 30, and 60min, solutions were col-
lected from the receiver side and replaced with 1mL of fresh
HBSS media [22]. Samples were collected from both sides after
90min, and the transwell membrane insert was placed in 1.5mL
of ice-cold 0.5mol sodium hydroxide/L and sonicated with a
probe-type sonic dismembrator (Biologics, Inc.); pHwas adjusted
to 7.0; all samples were injected directly to HPLC for analysis and
the quantitation was based on the standard curve of alkamides
and ketone 24. Transport experiments were performed at 37°C
and at 4°C. Total cellular protein was determined by the Coomas-
sie (Bradford) assay (Pierce Laboratories).
Transepithelial transfer of pure compounds and extracts
after treating with β-glucuronidase/sulfatase
Twenty µL of β-glucuronidase/sulfatase (Type H-5 from Helix po-
matia, 40 units/L; Sigma-Aldrich Co.) were added to the post-ex-
perimental apical and basolateral solutions and to cell homoge-
nates, and incubated overnight at 37°C to release the parent com-
pounds. These samples were then injected directly into HPLC.
Papp were determined by using the equation [12]:
Papp = (dQ/dt) (1/(A × C0))
where dQ/dt is the permeability rate constant (µmol/s), A is the
surface area of the membrane (cm2), and C0 is the initial concen-
tration of the compound (µM).
P‑gp assay
P‑gp activity was evaluated with fluorimetric measurement of
the intracellular accumulation of calcein produced by ester hy-
drolysis of the P‑gp substrate calcein-AM by using a Vybrant™
Multidrug Resistance Assay Kit (Gibco Invitrogen). Cells were
trypsinized and seeded into 96-well plates at 1.2 × 105 cells/cm2.
Cells were preincubated for 15min with pure compounds (Bauer
alkamides 8, 10, and 11 and ketone 24) or extracts at noncyto-
toxic concentrations; thereafter, calcein-AM was added and the
fluorescence measured after 1 h with a microtiter plate reader
Bio-Tek ELX 808 (Bio-Tek Instruments, Inc.) at 490 nm. The con-
trol wells received vehicle alone (DMSO in DMEM, 0.3% v/v). The
known P‑gp inhibitor, verapamil (> 99%, 10 µg/mL, included in
the kit), was used as a positive control.
Statistical analysis
Data are given as means ± S.D. Differences in cytotoxicity, Papp,
transport kinetics, permeation rate, and absorbance representing
calcein efflux by P‑gp among treatments were evaluated statisti-
cally by using one-way analysis of variance (ANOVA) and Tukeyʼs
multiple comparison tests in SAS 9.1 (SAS Institute, Inc.). Differ-
ences were considered significant at p < 0.05 and p < 0.01.
Results
!
Bauer alkamides 8, 10, and 11, as well as ketone 24, were all
present in Echinacea species studied, but with different profiles
(l" Table 1). Echinacea sanguinea ethanol extract had ~ 3× greater
Bauer alkamide 8 and ~ 6× greater Bauer ketone 24 than did the E.
pallida accession on a molar basis. The amount of Bauer alkamide
11 in E. pallidawas ~ 6× more than that of E. sanguinea, but Bauer
alkamide 10 content was similar in the two species. Bauer alka-
mide 8 and ketone 24 were more concentrated in both Echinea-
cea species than were Bauer alkamides 10 and 11.
Concentrations of Bauer alkamide 8 > 350 µM, Bauer alkamide
10 > 950 µM, Bauer alkamide 11 > 460 µM, and Bauer ketone
24 > 990 µM were significantly cytotoxic to Caco-2 cells when
compared with the control (0.3% v/v DMSO in DMEM, p < 0.05).
Ethanol extracts of E. sanguinea at 5mg/mL (containing
~ 450 µM total alkamides) and E. pallida at 20mg/mL (containing
~ 1150 µM total alkamides) were also significantly cytotoxic to
the cells. Therefore, 10, 25, 50, and 100 µM of pure Bauer alka-
mides, ketone 24, and E. sanguinea and E. pallida ethanol extracts
containing the same concentrations of each compoundwere used
for permeability studies.
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The uptake of Bauer alkamides 8, 10, and 11 increased linearly
and exhibited non-saturable transport across the tested concen-
trations (10–100 µM, l" Fig. 2A). Transport rates of Bauer alka-
mides 8, 10, and 11 in the basolateral to apical (BL–AP) direction
were nearly the same as those in the apical to basolateral (AP–BL)
direction at each tested time point (l" Fig. 2B, p > 0.05). The trans-
epithelial transport in the two directions was not saturated with-
in 90min, as shown in l" Fig. 2B. The transport of Bauer alka-
mides 8, 10, and 11 across Caco-2 cell monolayers was investi-
gated at both 37°C and 4°C to evaluate the effect of temperature
on alkamide transport (AP‑BL, l" Fig. 2C). No significant differ-
ences were found in the permeation rates of these three alka-
mides at 37°C compared with those at 4°C (p < 0.05).
Differences in permeability correlate with variations in alkamide
structure, and the rank of the permeability of the three alkamides
was Bauer alkamide 8 > 10 > 11 (l" Table 2 and Fig. 2A,B, and C).
When evaluating apparent permeability coefficients before de-
conjugation with β-glucuronidase (Papp, l" Table 2), we detected
no significant differences between alkamides tested as single
compounds and alkamides present in both E. sanguinea and E.
pallida extracts (p > 0.05).
After addition of the alkamides to the apical side of Caco-2mono-
layers, glucuronide metabolites of three alkamides in the E. san-
guinea extract were found in all compartments, including apical
and basolateral sides as well as cell lysates, comparedwith only in
the apical side for pure Bauer alkamide 8, in the apical side and
cell lysates for pure Bauer alkamide 10, as well as in the basolat-
eral side and cell lysates for pure Bauer alkamide 11 (l" Fig. 3A,B,
and C). Interestingly, glucuronide conjugates were only detected
basolaterally for Bauer alkamides 8 and 10 from the E. pallida ex-
tract (l" Fig. 3A and B), and only in the cell lysates for Bauer alka-
mide 11 from the E. pallida extract (p < 0.05, l" Fig. 3C).
The Papp for Bauer ketone 24 in E. sanguinea and E. pallida ethanol
extracts was 12.2 ± 3.2 and 17.1 ± 7.8 cm/s × 10−6, respectively,
with no significant difference between them (p > 0.05, l" Table
2), while Bauer ketone 24 was not found apically, basolaterally,
or in cell lysates when applied as a pure compound at any time
point (15–90min) across tested concentrations (10–100 µM).
Two unknown peaks were detected (retention times of 13.3 and
15.4min) in both apical and basolateral chambers and in cell ly-
sates after treating the Caco-2 cells with pure Bauer ketone 24,
but not for this same compound when present as a component
in the two plant extracts (l" Fig. 4B,C, and D). After β-glucuroni-
dase treatment, Bauer ketone 24 recovery, relative to the applied
amount, was significantly increased both basolaterally and in cell
lysates for this ketone when contained in E. sanguinea and E. pal-
lida extracts (l" Fig. 3D). Papp was significantly increased for the
three alkamides and Bauer ketone 24 in the E. sanguinea extract
and for Bauer alkamides 8 and 10 and ketone 24 in the E. pallida
extract when compared with single compounds after deconjuga-
tion with β-glucuronidase (p < 0.05, l" Table 2).
As shown in l" Fig. 5, Bauer alkamide 8 at 175 µM, Bauer alka-
mide 10 at 205 µM, and Bauer alkamide 11 at 230 µM, as single
compounds, significantly inhibited P‑gp activity (p < 0.05), but
Bauer ketone 24 was not active across the tested concentrations
(1–250 µM). The ethanolic extracts of E. sanguinea and E. pallida
significantly inhibited P‑gp at 1mg/mL (containing 85 µM of al-
kamide 8, 2 µM of alkamide 10, and 0.7 µM of alkamide 11) and
5mg/mL (containing 215 µM of alkamide 8, 25 µM of alkamide
10, and 45 µM of alkamide 11), respectively (l" Fig. 5).
Discussion
!
This study investigated the uptake and metabolism of three alka-
mides and a ketone, when introduced to cultures of the human
intestinal epithelial cell line, Caco-2, either as pure compounds
or as components of complex ethanolic extracts of Echinacea. Be-
cause Bauer alkamide 8 was absorbed by passive diffusion [35],
we expected that other alkamides would also be absorbed by a
similar mechanism across Caco-2 cells. This is supported by the
finding that the rate of membrane permeation of these three al-
kamides increased linearly with concentration, was not saturable
during the tested incubation period (15–90min), and was not
different in either direction of transfer (AP‑BL vs. BL‑AP,l" Fig. 2A
and B). Further, the transport of the three alkamides was temper-
ature independent (l" Fig. 2C), indicative of passive diffusion
through the Caco-2 cells [23].
The order of the uptake of the three alkamides was Bauer alka-
mide 8 > 10 > 11, consistent with Papp for Bauer alkamide 8 of
~ 2.5× and ~ 15× greater than that of Bauer alkamides 10 and 11,
respectively (l" Table 2). This trend for increases in hydrophilicity
giving rise to increases in their apparent permeability has also
been noted across the family of alkamides [9,24].
Monohydroxylated, monoepoxidized, and N-dealkylated metab-
olites were reported after incubation of parent Bauer alkamide 8
with NADPH and human liver microsomes [25]. But few studies
have investigated the Phase II biotransformation of alkamides
[14]. In our study, the amount of the parent compound increased
by ~ 1.5 to 4.2× for Bauer alkamides 8, 10, and 11 on the apical
and basolateral sides, or in cell lysates after β-glucuronidase incu-
bation, indicating that alkamides were seemingly N-glucuroni-
dated to some extent based on the amide structure (O-glucuro-
nide might not form because of steric hindrance,l" Fig. 1), reveal-
ing another important pathway for alkamide metabolism besides
cytochrome P450 (CYP) [10]. This finding is different from that of
Ardjomand-Woelkart et al. [14] showing that no glucuronide or
sulfate metabolite was present in the urine after oral administra-
tion of Bauer alkamide 8 both as a pure compound and in E. pur-
Table 1 The concentrations of alkamides and ketone in Echinacea ethanol extracts determined by HPLC.
Bauer alkamide 8 g/L
(mM)
Bauer alkamide 10 g/L
(mM)
Bauer alkamide 11 g/L
(mM)
Bauer ketone 24 g/L
(mM)
E. sanguinea
(PI 633672, 154 g/L)
3.23 ± 0.21
(13.07 ± 0.85)
0.14 ± 0.01
(0.56 ± 0.04)
0.03 ± 0.01
(0.12 ± 0.04)
3.82 ± 0.56
(17.52 ± 2.57)
E. pallida
(PI 63293, 100 g/L)
1.15 ± 0.10
(4.66 ± 0.40)
0.10 ± 0.01
(0.40 ± 0.04)
0.26 ± 0.03
(1.03 ± 0.11)
0.64 ± 0.04
(2.93 ± 0.18)
E. sanguinea and E. pallida ethanolic extracts were diluted by methanol for HPLC analysis (n = 9). All values are means ± SD. PI, accession number
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purea root extract in rats [14]. It may be that components not
found in E. purpurea that are specific to the Echinacea species
studied facilitate this metabolism. In our study, alkamide 8 as a
pure compound was not found as a glucuronide metabolite baso-
laterally but only apically. This suggests that there may be glucu-
ronidation of pure alkamide 8 in vivo but it might not be readily
detected if it is entirely transported to the intestinal lumen, be-
cause gut microbial β-glucuronidases would likely transform this
metabolite to the parent compound. Further study of alkamide
and ketone glucuronides (N- or O-) and their interaction with
intestinal cell transporters and other Echinacea constituents is
warranted.
The plant extracts did not affect transfer of alkamides as single
compounds before deconjugation with β-glucuronidase (l" Table
2), establishing that the transfer of alkamides was passive and
independent of the plant extract matrix for the two Echinacea
Fig. 2 Transport of pure Bauer alkamides 8, 10,
and 11 across Caco-2 cells. A Concentration de-
pendency of the transport of three alkamides.
B Non-saturable transport of three alkamides at
25 µM during the 90-min incubation period with no
difference between apical to basolateral (AP‑BL)
and basolateral to apical (BL‑AP) direction at each
time point. C The effect of temperature on the
transport of the three alkamides (37°C vs. 4 °C).
Means bearing different letters were significantly
different among three alkamides by ANOVA and
Tukeyʼs multiple comparison (p < 0.05). Data are
presented as the mean ± S.D (n = 6).
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species studied. Alkamide 8 in the plant extracts is seemingly a
non-separable mixture of (2E,4E,8Z,10 E/Z)-N-isobutyldodeca-
2,4,8,10-tetraenamide isomers, but this apparent mixture be-
haves similarly to the 90% pure (2E,4E,8Z,10Z)-N-isobutyldode-
ca-2,4,8,10-tetraenamide isoform in transferability before reac-
tion with β-glucuronidase (l" Fig. 3A, Table 2). After β-glucuroni-
dase hydrolysis, the plant extract alkamide 8 isomer mixture be-
haves similarly to alkamide 10 (l" Fig. 3A and B, Table 2), suggest-
ing that the plant extract alkamide 8 isomers may be similar to
each other in their metabolism and transfer; this remains to be
determined by comparing the pure alkamide 8 isomers. After β-
glucuronidase hydrolysis, recovery relative to initial amounts
was significantly increased in all compartments of the system, in-
cluding the apical and basolateral sides as well as the cell lysates,
for all three alkamides studied in E. sanguinea extract (l" Fig. 3).
These results suggest that other constituents in Echinacea species
might regulate the expression of MRP (multidrug resistance-as-
sociated protein) or OATP (organic anion transporter protein)
transporters, which in turn affect the permeation of glucuroni-
dated alkamides, because anionic conjugates (glutathione, glucu-
ronide or sulfate) cannot exit cells unless an MRP or OATP trans-
porter is present [26].
Pure Bauer ketone 24 might be metabolized by CYPs based on its
diene structure and the position of its ketone group. About 5% of
the Bauer ketone 24 was recovered in the basolateral side for the
compound as contained in two Echinacea species extracts (l" Ta-
Fig. 3 Glucuronidation of Bauer alkamides 8, 10, 11 and ketone 24 for pure
compounds or from plant extracts by Caco-2 cells. Before: prior to deconju-
gation with β-glucuronidase; After: subsequent to deconjugation with β-glu-
curonidase. The concentration of three Bauer alkamides and ketone 24 was
25 µM both for pure compounds and as found in the two Echinacea extracts.
A Bauer alkamide 8. B Bauer alkamide 10. C Bauer alkamide 11. D Bauer
ketone 24.* Significantly different compared with the recovery relative to the
initial amount before the enzyme treatment by two-sample t-test (p < 0.05).
Data are presented as the mean ± S.D. (n = 6).
Table 2 Apparent permeability coefficients (Papp) for pure Bauer alkamides, ketone 24, and extracts across the Caco-2 monolayer.
Papp (cm/s × 10−6)
Bauer alkamide 8 Bauer alkamide 10 Bauer alkamide 11 Bauer ketone 24
Before After Before After Before After Before After
Single compound 43.8 ± 11.2a 39.8 ± 13.4b 17.7 ± 8.8a 18.3 ± 5.9b 2.8 ± 1.5a 9.7 ± 2.3*a ND ND
E. sanguinea 54.6 ± 13.2a 76.8 ± 11.7*a 12.9 ± 5.6a 28.4 ± 4.1*a 3.7 ± 1.9a 8.2 ± 2.4*a 12.2 ± 3.2a 22.9 ± 6.3*a
E. pallida 41.3 ± 7.4a 65.2 ± 6.8*a 14.7 ± 4.2a 22.3 ± 7.9*a 5.4 ± 2.5a 4.3 ± 1.9b 17.1 ± 7.8a 28.4 ± 6.3*a
All values are means ± SD (n = 9). TEER was 460–573 Ω · cm2. In each column, means of Papp bearing different letters were significantly different (p < 0.05). Bauer alkamides 8, 10,
and 11 and ketone 24 were 10–100 µM for pure compounds. Two herb extracts were diluted to contain same concentrations of Bauer alkamides 8, 10, or 11 or ketone 24 as the
pure compounds. Before: prior to deconjugation with β-glucuronidase; After: subsequent to deconjugation with β-glucuronidase. * Significantly different compared with the Papp
before deconjugation with β-glucuronidase by ANOVA and Tukeyʼs multiple comparison, p < 0.05
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ble 2). Bauer ketone 24 transferred across the Caco-2 monolayers
with an apparent permeability of 10 ± 3 cm/s × 10−6, as extracted
and isolated from E. pallida roots [27], similar to that seen in the
present study from E. sanguinea and E. pallida; Papp for Bauer ke-
tone 24 was 12–17 cm/s × 10−6 (l" Table 2). The difference in per-
meability of Bauer ketone 24 as a pure compound versus that in
extracts might be due to the effects of other extract constituents,
because several Echinacea species extracts (11.2–2447 µg/mL)
inhibited CYP 2C19, 2D6, and 3A4 by 20–100%, and alkamides
contributed to CYP inhibitory effects seen with Echinacea prepa-
rations [28]. E. purpurea root selectively modulated the catalytic
activity of CYP3A and CYP1A2 at hepatic and intestinal sites by
the interaction between Echinacea and enzyme substrates [29],
although Gurley et al. reported minor activities of E. purpurea on
CYP1A2, CYP2E1, CYP2D6, and CYP3A4 phenotypes [30]. In our
study, Bauer alkamides 8, 10, and 11 were incubated with ketone
24 at 10–100 µM, but ketone 24was still totallymetabolized (data
not shown). This implies that the CYP isoforms inhibited by those
alkamides were not involved in the biotransformation of ketone
24, although we cannot rule out the possibility that the doses of
those alkamides were too low to exhibit inhibitory effects.
Although E. pallida polyacetylenes and polyenes are considered
to have low chemical stability, after 72 h, 100 µM ketone 24 at
37°C in RPMI 1640 medium, hydroperoxide intermediate forma-
tion was about 25% of the parent compound, and hydroxylated
derivatives were not observed [31]. Therefore, the unknown
more hydrophilic metabolites of ketone 24 were formed by
Caco-2 cell metabolism during the 90min incubation period,
rather than non-metabolic oxidation. The identification of the
ketone metabolites and herbal constituents that inhibit ketone-
metabolizing enzymes is required.
P‑gp actively effluxes a wide range of structurally diverse anti-
cancer agents, and P‑gp-mediated multidrug resistance (MDR)
has been associated with inhibition of caspase-dependent tumor
cell apoptosis [32]. One strategy for reversal of MDR in cells ex-
pressing ATP-Binding Cassette (ABC) transporters is a combined
use of anticancer drugs with modulators [33]. In our study, ex-
tracts of E. sanguinea and E. pallida significantly inhibited P‑gp-
mediated efflux of calcein AM, a substrate for P‑gp, indicating
that alkamides were potentiated in the inhibition of P‑gp by oth-
er extract constituents (l" Fig. 5). For example, quercetin at
100 µM inhibited 30% of P‑gpmediated efflux of [3H]-taxol in Ca-
co-2 cells [34]. The concentrations of Echinacea plant extracts
that inhibited P‑gp in our study were greater than shown previ-
Fig. 5 The effects of Bauer alkamides 8, 10, 11, and ketone 24 on P-gly-
coprotein transporter activity. Control was 0.3% v/v DMSO in PBS. Verapa-
mil was used as a positive control at 10 µg/mL. *,** Significantly different
compared with control by two-sample t-test (p < 0.05, 0.01, respectively).
Data are presented as the mean ± S.D (n = 6). The ethanolic extract of E.
sanguinea at 1mg/mL contained 85 µM of alkamide 8, 2 µM of alkamide 10,
and 0.7 µM of alkamide 11. The ethanolic extract of 5mg/mL of the E. pal-
lida extract contained 215 µM of alkamide 8, 25 µM of alkamide 10, and
45 µM of alkamide 11.
Fig. 4 HPLC chromatograms of Bauer ketone 24 across Caco-2 cell mono-
layers as a pure compound and from Echinacea species. A Bauer ketone 24
standard at 100 µM (retention time 17.6min). B Bauer ketone 24 (100 µM)
was not detected in the basolateral supernatant fluid, but two more hydro-
philic metabolites were detected (retention time 13.3 and 15.4min). C Ba-
uer ketone 24 is shown in the basolateral side after apically applied E. sangui-
nea containing 100 µM of ketone 24 (retention time 17.6min). D Bauer ke-
tone 24 is shown in the basolateral side after apically applied E. pallida con-
taining 100 µM of ketone 24 (retention time 17.6min).
272
Qiang Z et al. Echinacea sanguinea and… Planta Med 2013; 79: 266–274
Original Papers
D
ow
nl
oa
de
d 
by
: I
P-
Pr
ox
y 
Io
wa
_S
ta
te
_U
ni
ve
rs
ity
, I
ow
a 
St
at
e 
Un
ive
rs
ity
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
ously in human proximal tubular kidney cells, showing that the E.
pallida extract was the most active at 3 µg/mL compared with E.
angustifolia and E. purpurea both at 30 µg/mL [15]. More interest-
ingly, Bauer ketone 24 was found to be the most efficient constit-
uent isolated from E. pallida to inhibit P‑gp at 3–200 µg/mL,
equivalent to 14 µM–933 µM [15]. But in our study, Bauer ketone
24 was ineffective, which might be due to the difference in the
cell lines used, to themetabolism of Bauer ketone 24, or to extract
preparation. The extraction ratio (raw material weight: final so-
lution volume) was 12:1 for the ethanol extract in our study vs.
125:1 for the n-hexane extract in the study of Romiti et al. [15].
Although alkamides are probably mostly absorbed in the small
intestine, because we have shown that alkamides are apparently
glucuronidated, the alkamide glucuronides will be effluxed to the
lumen to some extent in intestinal cells, (except in the case of the
alkamides in E. pallida), and these metabolites would also be sus-
ceptible to biliary excretion into the intestine. Although N-glucu-
ronides are more slowly hydrolyzed by gut bacterial β-glucuroni-
dase, than are O- or S-glucuronides [35], the parent alkamides
would still be available to act in the large intestine. In addition,
alkamides were highly permeable, which permits their interac-
tion with P‑gp, since its binding sites are either inside the bilayer
or at the inner leaflet of the cell membrane [36]. Although glucur-
onidation may prevent tissue uptake of the alkamides, glucuroni-
dase produced by the liver and neutrophils [37,38] may convert
the glucuronide conjugates back to the parent compounds, and
alkamides may enter the hepatic portal vein at relatively high
concentrations, possibly permitting alkamide inhibition of P‑gp
in tissues throughout the body.
In conclusion, Bauer alkamides 8, 10, and 11 were transferred
across Caco-2 cells, independent of extract matrix, thus the re-
sults of experiments testing efficacy of pure compounds may rea-
sonably be extrapolated to results obtained from cruder extracts
of plant materials containing these compounds. Alkamides and
Bauer ketone 24 in Echinacea species extracts had a more exten-
sive metabolism in the Caco-2 cells than did pure compounds,
and extract matrices may have facilitated the metabolism of alka-
mides and ketones. Bauer alkamides 8, 10, and 11, as well as E.
sanguinea and E. pallida extracts, inhibited P‑gp-mediated efflux
in Caco-2 cells. Considering the increasing knowledge about the
role of P‑gp in cancer resistance and the global increase in the use
of Echinacea preparations, further studies in humans are re-
quired to specifically investigate the uptake and metabolism of
alkamides and ketones derived from natural plant products.
Mechanisms for enhanced metabolism by accompanying constit-
uents in plant extracts should also be established. Because Echi-
nacea supplements are usually ingested on a chronic basis, their
long-term effects on themetabolizing enzymes and expression of
efflux transporters need to be investigated, especially for the
ability to potentiate drug efficacy.
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